Nath Bio-Genes opened lower at ₹134.20, compared with its previous close of ₹135.79. During today's session, the stock has traded between ₹134.20 and ₹139.20, with an average traded price of ₹136.65. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Nath Bio-Genes is now worth
₹ 4,185.00
resulting in a loss of
₹ 5,815.00 (58.15%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.20 (-0.15%)
Day High
₹139.20
Day Low
₹134.20
Day Open
₹134.20
Prev Close
₹135.79
Volume
10,330
Value Traded
₹0.14 Cr
1W Return
0.97%
1M Return
-8.25%
3M Return
-17.70%
6M Return
-11.34%
1Y Return
-23.56%
Market Cap (₹ Cr.)
258
PE Ratio
6.70
PB Ratio
0.38
Dividend Yield
1.47%
ROE
6.12%
ROCE
8.86%
Book Value (₹)
358.06
Face Value (₹)
10.00
EPS (TTM)
16.98
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.97%
6 Week
-
1 Month
-8.25%
3 Month
-17.70%
9 Month
-7.86%
Nath Bio-Genes shareholders approve ₹2 dividend, director reappointments
Shareholders approved a final dividend of ₹2 per equity share for FY26. All five AGM resolutions passed with over 99.98% support via remote e-voting. Hitesh Rajnikant Purohit re-appointed as Independent Director for second five-year term. Managing Director Satish Kagliwal's remuneration revised effective January 1, 2026.
19 days agoNath Bio-Genes sets Sep 11 record date for AGM and dividend
Record date for 33rd AGM and dividend is set for September 11, 2026. Annual General Meeting scheduled for September 24, 2026 at 11:00 am. Meeting will be held via Video Conferencing or Other Audio Visual Means.
1mo agoNath Bio-Genes Q1FY27 profit rises 12% on revenue surge
Nath Bio-Genes reported a 12% YoY rise in standalone net profit to ₹32.66 crore for Q1FY27, driven by a 15% surge in revenue to ₹322.84 crore. Consolidated net profit rose 14% YoY to ₹32.26 crore, reflecting strong demand in its seed cultivation segment.
2mo agoNath Bio-Genes promoters hold 45.60% stake, encumber shares
Nath Bio-Genes (India) Limited disclosed a promoter holding of 45.60%, or 86,64,902 equity shares, as of March 31, 2026. The promoters encumbered 11.94 lakh shares during FY26, a move previously disclosed. The filing lists 17 entities within the promoter and promoter group categories.
3mo agoNath Bio-Genes Q4 FY26 Earnings Call: Revenue Up 19%, Audio Recording Submitted
Nath Bio-Genes (India) Limited reported FY26 standalone revenue of Rs. 43,159.72 Lakhs, up 19% YoY, with net profit of Rs. 4,442.57 Lakhs. The Uzbekistan JV debuted with INR 15 crores contribution to consolidated revenue. The company submitted the audio recording of its Q4 FY26 conference call to BSE and NSE on May 11, 2026, per SEBI Regulation 30, signed off by CFO Amol Gupta.
5mo agoNath Bio-Genes Board Meeting May 4 & Earnings Call May 5 for Q4FY26 Results
Nath Bio-Genes has scheduled a comprehensive Q4FY26 results disclosure process with board meeting on May 4, 2026 to approve audited financial results and consider dividend recommendations, followed by earnings conference call on May 5, 2026 at 4:00 PM IST hosted by Go India Advisors featuring key management personnel including MD Satish Kagliwal and CFO Amol Gupta.
5mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹414.25 | -0.05% | ₹14,384.95 | 22.39 | +3.03% | |
| ₹396.60 | +0.90% | ₹9,077.77 | 11.89 | +6.93% | |
| ₹173.26 | +3.84% | ₹7,946.93 | 18.35 | +65.64% | |
| ₹447.20 | +0.89% | ₹3,834.86 | 23.84 | -13.95% | |
| ₹710.85 | +1.20% | ₹3,656.55 | 14.57 | -33.18% | |
| ₹218.68 | -0.91% | ₹2,264.47 | 18.52 | +21.49% | |
| ₹100.37 | +1.37% | ₹2,010.09 | 57.73 | +5.12% | |
| ₹91.00 | +3.43% | ₹1,885.61 | 23.86 | -30.49% | |
| ₹97.06 | -0.45% | ₹1,478.07 | 17.82 | +40.08% | |
| ₹284.30 | -1.20% | ₹1,413.70 | 11.49 | +11.08% | |
| ₹161.27 | -1.18% | ₹1,005.85 | 23.86 | +10.94% | |
| ₹90.88 | +1.53% | ₹953.67 | 33.02 | -26.22% |
An investment of ₹10,000 made 5 years ago in Nath Bio-Genes is now worth
₹ 4,185.00
resulting in a loss of
₹ 5,815.00 (58.15%)
Note: Past profits do not guarantee future returns.
